NextCure, Inc.
NASDAQ Global SelectTotal Valuation
NextCure, Inc. carries a market capitalization of 28.25M, placing it among publicly traded companies globally. Its enterprise value stands at -9.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 28.25M |
| Enterprise Value | -9.97M |
Share Statistics
NextCure, Inc. currently has 4.07M shares outstanding.
| Shares Outstanding | 4.07M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.54 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | -0.19 |
| P/OCF Ratio | -0.19 |
Financial Position
NextCure, Inc. maintains a current ratio of 3.47, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.47 |
| Quick Ratio | 3.13 |
| Debt / Equity | 29.66 |
| Debt / EBITDA | -0.10 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -195.22 |
| Return on Assets (ROA) | -121.60 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
NextCure, Inc.'s stock has gained approximately 61.23711% over the past 52 weeks. The 50-day moving average sits at 5.05, while the 200-day moving average is 9.10.
| Beta (5Y) | N/A |
| 52-Week Price Change | 61.23711% |
| 50-Day Moving Average | 5.05 |
| 200-Day Moving Average | 9.10 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -37.37M, while operating income came in at -38.82M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -38.82M |
| Pretax Income | -42.75M |
| Net Income | -42.75M |
| EBITDA | -37.37M |
| EBIT | -38.82M |
| Earnings Per Share (EPS) | -9.70 |
Balance Sheet
NextCure, Inc. holds 20.09M in cash and equivalents against 3.60M in total debt, resulting in a net debt position of -15.26M. Total book value stands at 12.15M, with working capital of 15.84M providing operational flexibility.
| Cash & Cash Equivalents | 20.09M |
| Total Debt | 3.60M |
| Net Debt | -15.26M |
| Equity (Book Value) | 12.15M |
| Book Value Per Share | 2.99 |
| Working Capital | 15.84M |
Cash Flow
NextCure, Inc. produced -36.98M in operating cash flow over the past twelve months.
| Operating Cash Flow | -36.98M |
| Capital Expenditures | N/A |
| Free Cash Flow | -36.98M |
| FCF Per Share | -8.39 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -331.21 |
| FCF Yield | -524.34 |
Stock Splits
NextCure, Inc.'s most recent stock split took place on July 14, 2025 with a 12:1 split ratio.
| Last Split Date | 7/14/2025 |
| Split Ratio | 12:1 |
Scores
NextCure, Inc. posts an Altman Z-Score of -32.96, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -32.96 |